HCG Q1 FY27 Earnings Call Transcript Released; Revenue Up 13% to ₹695.1 Crore
HCG reported Q1 FY27 revenue of ₹695.1 crore, up 13% YoY, driven by an 11% increase in patient volumes. Adjusted EBITDA grew 20% to ₹133.9 crore, with margins improving to 19.4%. The new North Bangalore hospital contributed ₹6.7 crore in its first quarter. HCG aims for 24-25% EBITDA margins in the coming years.
The announcement contains key financial results, strategic updates, and future growth plans, which are material information for investors and analysts, thus having a high impact.
The company reported strong year-on-year growth in revenue and EBITDA, improved margins, and provided positive outlook for future growth and profitability. The successful commissioning of a new hospital and strategic initiatives like divestment of non-core assets and rights issue further strengthen the positive sentiment.
Healthcare Global Enterprises Limited (HCG) has released the transcript of its earnings call held on August 07, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The company reported a revenue of ₹695.1 crore (INR6,951 million), marking a 13% year-on-year growth. This growth was broad-based, with 16 out of 25 centers, excluding the newly operational North Bangalore hospital, achieving their highest ever quarterly revenues. Patient volumes increased by 11%, and Average Revenue Per Patient (ARPP) grew by 2%, driven by a favorable payor mix.
The company's focus remains on delivering sustainable, profitable growth, driving operational excellence, and enhancing patient experience. The divestment of the Fertility business and a successful rights issue have strengthened the company's balance sheet and strategic focus. Adjusted EBITDA increased by 20% year-on-year to ₹133.9 crore (INR1,339 million), with EBITDA margins improving to 19.4% from 18.2% in Q1 FY26.
The North Bangalore hospital, which commenced operations in May 2026, contributed ₹6.7 crore (INR67 million) in its first quarter. The company is also progressing with its capacity expansion plans, aiming to add 65 beds in FY27, 520 beds in FY28-29, and 230 beds in FY30, with a significant portion coming from brownfield projects. HCG has also invested in advanced technologies, including a new LINAC in Rajkot and two surgical robotic systems. The company expressed confidence in achieving 24-25% EBITDA margins in the next few years and is exploring value-accretive M&A opportunities.
What to do with a filing like this
Healthcare Global Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Healthcare Global Enterprises Limited. Read the original for the full detail.